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Abstract
The aim of this collaborative study on Duchenne muscular dystrophy and Becker muscular dystrophy is to determine the pre-
valence and to develop data on such patients as a prelude to the development of registry in Hong Kong. Information on clinical and
molecular findings, and patient care, was systematically collected in 2011 and 2012 from all Pediatric Neurology Units in Hong
Kong. Ninety patients with dystrophinopathy were identified, and 83% has Duchenne muscular dystrophy. The overall prevalence
of dystrophinopathy in Hong Kong in 2010 is 1.03 per 10 000 males aged 0 to 24 years. Among the Duchenne group, we observed
a higher percentage (40.6%) of point mutations with a lower percentage (45.3%) of exon deletions in our patients when compared
with overseas studies. Although we observed similar percentage of Duchenne group received scoliosis surgery, ventilation
support, and cardiac treatment when compared with other countries, the percentage (25%) of steroid use is lower.
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Duchenne muscular dystrophy and Becker muscular dystrophy
are both dystrophinopathy due to mutations of the Duchenne
muscular dystrophy gene on the X-chromosome and predomi-
nantly affect male. The Duchenne muscular dystrophy gene
mutations could result in complete loss of dystrophin protein that
lead to the severe condition called Duchenne muscular dystro-
phy, or there is only partial decrease in dystrophin protein that
lead to Becker muscular dystrophy the milder form. Dystrophi-
nopathy, including both Duchenne muscular dystrophy and
Becker muscular dystrophy, is the commonest neuromuscular
disorder in children. It is characterized by progressive muscle
weakness and muscle degeneration as the child grows. The rate
of deterioration is much faster in the Duchenne muscular dystro-
phy when compared to the milder Becker muscular dystrophy.
From the previous natural history studies, the boys with Duch-
ennemuscular dystrophy lost ambulation between 6 and 11 years
old, developed respiratory and cardiac complications in the teen-
age years, and died in the late 10s or early 20s.1-3 Boys with
Becker muscular dystrophy, on the other hand, have a later age
of onset and a more variable clinical weakness with a slower pro-
gression. Most of them keep walking on entering adulthood.
Since the discovery of Duchenne muscular dystrophy gene
in 1986 by Monaco et al4 and the dystrophin protein in 1987
by Hoffman et al,5 there were numerous researchers trying to
replace the deleted dystrophin in patient muscles and to iden-
tify possible molecular therapies for Duchenne muscular dys-
trophy/Becker muscular dystrophy. These include direct gene
repair at DNA level, exon skipping, or stop codon read through
at messenger RNA level, and even utrophin upregulation as the
compensatory strategies. Some of these approaches are only
applicable to mutations caused by specific exon deletion; oth-
ers are targeted at mutations due to small rearrangement.6
The current study served as an initial step to gather the manda-
torydata set includingdemographic information, clinical, andmole-
cular findings, aswell as their intervention andcare, for this groupof
patients, and served as a prelude to the development of registry that
allow the future coordination of possible clinical trial readiness.
In Hong Kong, all the children diagnosed to have dystrophi-
nopathy will be under the care of pediatrics neurologists who are
also the main coordinators for the multidisciplinary care for this
group of children following the standard of care guideline. Once
the diagnosis was confirmed, besides regular follow-up by the
neurology team, the affected child also had regular assessments
by the cardiology and the respiratory teams. Regular cardiac
assessment by cardiologist included echocardiogram arranged
at once every 1 to 2 years before the age of 10 years, and once
every year after the age of 10 years old onwards. For the respira-
tory monitoring, regular nocturnal oxygen saturation study at
yearly interval was arranged when the child lost ambulation. If
scoliosis was suspected, orthopedic follow-up and regular spine
X-ray evaluation would be arranged.
Materials and methods
This is a collaborative study jointly participated by all the 10 Neurology
units of the Pediatrics departments in all regional hospitals under the
Hospital Authority (HA) of Hong Kong. This extensive collabora-
tion allows us to capture almost all the affected patients with
Duchenne muscular dystrophy under the age of 18 years old in
Hong Kong. Patients with confirmed diagnosis of either Duchenne
muscular dystrophy or Becker muscular dystrophy and had been
regularly follow-up by the Pediatrics Neurology teams between June
2006 and December 2010 were included. The diagnosis of dystro-
phinopathy was based on either genetic mutations and/or abnormal
expression of dystrophin immunohistochemical stainings in mus-
cle biopsy. In Duchenne muscular dystrophy, the dystrophin immu-
nolabeling was essentially absent while in Becker muscular
dystrophy, it was present but reduced. In some patients older than
12 years old, the diagnosis could also be confirmed by the clin-
ical course. Patients with Duchenne muscular dystrophy lost
ambulation on or before 12 years old, while those who continued
to walk after the age of 12 years without steroid treatment were
classified as having Becker muscular dystrophy.
Clinical data, including date of birth, clinical diagnosis, genetic
findings, performance of muscle biopsy, age at loss of ambulation, and
history of cardiomyopathy, scoliosis, and feeding problems, were sys-
tematically collected between June 2011 and June 2012. Information
on the oral steroid use, ventilator care, scoliosis surgery, and gastro-
stomy were also obtained. This study was approved by Institutional
Review Board of all the participating hospitals.
Results
Prevalence
As of December 2010, 90 individuals with dystrophinopathy
were identified. Two age-specific prevalence of dystrophinopa-
thy among males were calculated. For those male in the age-
group of 0 to 14, the prevalence is 1.14 per 10 000 males, and
for those in the age-group of 15 to 24 years, the prevalence is
0.85 per 10 000 males. The overall prevalence of dystrophino-
pathy in Hong Kong in 2010 is 1.03 per 10 000 males aged 0 to
24 years.
Age Range
Among the whole group, Seventy-five patients (83%) have
Duchenne muscular dystrophy and 15 patients (17%) have
Becker muscular dystrophy. Most of the patients were between
6 and 25 years old. The age range for patients with Duchenne
muscular dystrophy was 0.58 to 34.55 years with 48 (64%)
patients were above 12 years old. For those patients identified
to have Becker muscular dystrophy, their age ranged from 9.54
to 24.88 years (Figure 1).
Diagnosis
For the diagnostic confirmation, among the 75 patients with
Duchenne muscular dystrophy, 85.3% of patients had genetic
study and 65% of patients had muscle biopsy. Around half
(54.7%) of this group had both genetic study and muscle biopsy
done, while 33% had only genetic testing and 12% had only
muscle biopsy performed. For the 15 patients identified having
Becker muscular dystrophy, similar percentage of patients had
muscle biopsy (80%) and genetic study (73%). Again around
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half of the group (53.3%) had both genetic study and muscle
biopsy, with 26.7% had only genetic study, and 13.3% had only
muscle biopsy (Table 1).
Clinical Presentation and Interventions
In all, 21 patients had been started on oral steroid (predniso-
lone), with 19 patients from the Duchenne muscular dystro-
phy group but 2 from the Becker muscular dystrophy group
(Table 1). The steroid used was oral prednisolone given daily.
The mean steroid starting age (+1 standard deviation [SD])
was 8.45 + 2.0 years, with the age ranged from 4.3 to 12.3
years (Figure 2). For the 12 patients who had stopped steroid,
the mean (+1 SD) steroid stopping age was 10.67 + 1.89
years, with the age ranged from 8 to 13.3 years (Figure 2). The
mean duration of steroid use was only 2.1 years. The most
common reasons for stopping steroid was loss of ambulation,
obesity, and behavioral problems. Only one-fifth of the
patients who had been started on steroid continued the treat-
ment after loss of ambulation. The mean age (+1 SD) of loss
of ambulation was 10.7 + 1.5 years for those who had not
been on steroid and was similar to those who had been on ster-
oid (10.6 + 1.3 years).
Most children with Duchenne muscular dystrophy devel-
oped scoliosis in their early 10s. Of the 60 patients with DMD
aged after 11 years old, a quarter of this group (14 patients) had
undergone posterior spinal fusion. The mean age (+1 SD) for
the scoliosis surgery was 13.6+ 1.4 years, with the earliest age
for surgery at 12 and the latest at 15.1 years (Figure 3).
Among the 60 patients who were either at or older than
11 years old in the Duchenne muscular dystrophy group,
one-third of the group (19 patients) required noninvasive ven-
tilation with the mean starting age (+1 SD) at 17.4+ 5.0 years
with the age ranged from 13.1 to 23.4 years (Figure 4). Twenty-
three patients (two-third of the group) had echocardiographic
evidence of cardiomyopathy and were started on cardiac med-
ications. The mean age+1 SD for starting cardiac medication
was 18.2 + 3.6 years (Figure 5). The first-line treatment was
angiotensin-converting enzyme inhibitors including enalapril,
captopril, perindopril, and ramipril. b-Blockers, diuretics, and
digoxin were the add-on treatment if progressive heart failure
developed. Only 2 patients had undergone gastrostomy, with one
Table 1. Total Number and Percentages of Patients With Duchenne
Muscular Dystrophy and Becker Muscular Dystrophy Undergoing the
Diagnostic Procedures and the Different Interventions.
Patients With
Duchenne
Muscular
Dystrophy
No. of Cases (75) (%)
Patients With
Becker Muscular
Dystrophy
No. of Cases (15) (%)
Age <15 37 (49) 9 (53)
Age >15 38 (51) 7 (47)
Muscle biopsy
done
49 (65) 12 (80)
Genetic mutation
study
64 (85) 11 (73)
Steroid treatment 19 (25) 2 (14)
Scoliosis surgery 14 (19) 0 (0)
Cardiac treatment 23 (31) 1 (7)
Noninvasive
ventilation
19 (25) 1 (7)
Gastrostomy 2 (3) 0 (0)
Figure 2. Box and whiskers for steroid starting age (n ¼ 21) and
steroid stopping age (n ¼ 12) in years.
Figure 3. Box and whiskers for the age of scoliosis surgery (n¼ 14) in
years.
Figure 1. Number of patients with Duchenne muscular dystrophy
and Becker muscular dystrophy at different age range in years.
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at the age of 22.1 years and the other at 26.6 years (Table 1).
Four patients died during the followed up period, with 1 patient
at the age of 15.1 years and 3 patients in their 20s (23.1 years,
23.5 years, and 26 years).
Among the 15 patients with Becker muscular dystrophy,
most enjoyed stable health with only 1 patient had cardiomyo-
pathy and 1 required noninvasive ventilation due to obstructive
sleep apnea syndrome. Two patients were put on oral steroid.
Mutation Analysis
In Hong Kong, the genetic study for dystrophinopathy was car-
ried out by the Clinical Genetic Service under the Hong Kong
Department of Health. In the Clinical Genetic Service, multi-
plex polymerase chain reaction was used at the early years.
With modification of the test, exon duplications could be
detected. Since 2004, multiplex ligation-dependent probe
amplification that could detect both exon deletions and
duplications with whole gene coverage was used, and small
rearrangements or point mutations were identified either by
direct Sanger sequencing of the entire coding region or by
initial mutation screening with denaturing high-performance
liquid chromatography followed by Sanger sequencing. If
those patients suspected to have Duchenne muscular dystrophy
and had initial negative findings onmultiplex ligation-dependent
probe amplification, further testing with direct sequencing
would be arrange to confirm the diagnosis.
Seventy-five patients of the whole group had undergone
mutation analysis. Most mutations were caused by large exon
deletions (49.3%), followed by point mutations (37.3%) and
large exon duplication (9.4%). For the point mutations, these
include the small deletions or insertions, single-base changes,
and splicing mutations. Three patients did not have any muta-
tion identified. A higher percentage (40.6%) of point mutation
was observed in patients with Duchenne muscular dystrophy
(Tables 2 and 3).
Among the Duchenne muscular dystrophy group with
identified mutations, 12 mutations had not been reported pre-
viously. For the 26 patients identified to have point muta-
tions, most had nonsense mutations (61.5%), with others
Figure 4. Box and whiskers for noninvasive ventilation (NIV) starting
age (n ¼ 20) in years.
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Figure 5. Box and whiskers for cardiac drug starting age (n ¼ 24) in
years.
Table 2. Mutation Analysis Result of the Whole Group in Patients
With Duchenne Muscular Dystrophy and Becker Muscular
Dystrophy.
Distribution
of Mutation
Overall
95% Confidence
Interval
No. of
Cases
% of
Cases
Exon deletion 37 49.3 37.6-61.1
Exon duplication 7 9.3 3.8-18.3
Point mutation/
small rearrangement
28 37.3 26.4-49.3
No mutation found 3 4.1 0.8-11.3
Total 75 100
Table 3. Mutation Analysis Result Comparison Between Patients
With Duchenne Muscular Dystrophy and Becker Muscular
Dystrophy.a
Distribution
of Mutation
Duchenne Muscular
Dystrophy
Becker Muscular
Dystrophy
No. of
Cases
% of Cases
(95% CI)
No. of
Cases
% of Cases
(95% CI)
Exon deletion 29 45.3 (33.7-57.4) 8 72.7 (43.4-90.3)
Exon duplication 6 9.4 (4.4-18.9) 1 9.1 (1.6-37.8)
Point mutation/
small rearrangement
26 40.6 (29.5-52.9) 2 18.2 (5.1-47.7)
No mutation found 3 4.7 (1.6-12.9) 0 0
Total 64 100 11 100
aSome of the value is zero and to make the analysis possible, 0.5 was added to
each value for calculation.
Note. CI: confidence interval.
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had indel mutations (27%) and splice site mutations (11.5%)
(Figure 6). For the 29 patients identified to have exon dele-
tions, most were in the 30 hot spot (58%) with less were in
the 50 hot spot (27.6%) and outside hot spots region. Only
6 patients had exon duplications with mutations involved all
regions. Among the 36 patients with exon deletions/duplica-
tions, 5 patients have out-of-phase in-frame mutation by pre-
diction (Tables 2-6).
For the Becker muscular dystrophy group, among the iden-
tified mutations, 1 mutation had not been reported in previous
literatures. Of the 11 patients, 8 had exon deletions with 63.5%
occurred at 50 hot spot and the rest at the 30 hot spot. Only
1 patient had duplication. Most mutations are in-frame by
prediction except 3. The point mutations identified were only
associated with splice site mutation. (Tables 2-6) (Figure 6).
Discussion
Prevalence
Aprevious studyhadconfirmed that dystrophinopathywas themost
common neuromuscular disease in Hong Kong.7 From the current
study, the overall local prevalence of dystrophinopathy in 2010 is
1.0 per 10 000 males aged 0 to 24 years. Two age-specific preva-
lence of dystrophinopathy amongmales were calculated. For those
male in the age-group of 0 to 14, the prevalence is 1.14 per 10 000
males, and for those of the age-group of 15 to 24 years, the preva-
lence is 0.85per 10000males.Thenumberwas calculatedusing the
Hong Kong population statistics of male aged 0 to 24 years in the
mid-2010 (HongKong Special Administrative Region, Census and
Table 4. Point mutations or small rearrangements for DMD and BMD patients (Reference sequence: NM_004006.2).
DMD Point Mutation
Exon 6/c.453T>A, Tyr151* Exon 34/c.4729C>T, Arg1577*
Exon 12/c.1375G>T, Glu459*a Exon 41/c.5800del7þc.5845_5846ins14a
Exon 13/c.1594C>T, Gln532* Exon 44/c.6385_6388delAAGAa
Exon 16/c.1873C>T, Gln625* Exon 53/c.7755G>A, Tyr2585*
Exon 16/c.1843C>T, Glu615* Exon 53/c.7798_7799insCA, Arg2600Thrfs*15a
Exon 17/c.2086del13, Val696Lysfs*29 Exon 56/c.8224C>T, Glu2742*a
Exon 20/c.2601delAA, Gln869Valfs*5 Exon 58/c.8608C>T, Arg2870*
Exon 23/c.2968C>T, Gln990* Exon 59/c.8745G>A, Trp2915*
Exon 26/c.3556G>T, Glu1186* Exon 61/c.9156_9157insT
Exon 30/c.4099C>T, Gln1367* Exon 62/c.9204_9207delCAAA
Exon 32/c.4375C>T, Arg1459* IVS36-9G>A
Exon 32/c.4499C>A, Ser1500*a IVS45-1G>Ta
Exon 33/c.4570A>T, Lys1524* IVS70þ1G>A
BMD Point Mutation
Exon 18/c.2169-1_2169GG>TTa Exon 25/c.3432þ1G>A, skip exon 25b
Abbreviations: DMD, Duchenne Muscular Dystrophy; BMD, Becker Muscular Dystrophy.
aMutations that have not been reported in the literature.
bIn-frame mutation by prediction.
Table 5. Exon Deletion for Patients With Duchenne Muscular
Dystrophy and Becker Muscular Dystrophy.
50 Hot Spot
(Exons
3-19)
30 Hot Spot
(Exons
42-60)
Spanning
From 50 to 30
Hot Spots Other
Duchenne
muscular
dystrophy
Del 2-17 (2) Del 43 Del 3-43 Del 63-79
Del 3a Del 44 Del 12-43a
Del 5-7 Del 45 (2)
Del 7 Del 45-50 (2)
Del 8-9 Del 46-47
Del 10-19b Del 46-48 (2)
Del 46-49
Del 46-51
Del 48-50 (3)
Del 49-52
Del 50
Del 53
Del 55-60
Del 56-57a,b
(n ¼ 7) (n ¼ 19) (n ¼ 2) (n ¼ 1)
Becker
muscular
dystrophy
Del 3a Del 45-53a
Del 3-5 (3)a Del 49-52
Del 3-6 Del 52-53a
(n ¼ 5) (n ¼ 3)
Abbreviations: n, number of patient for each subgroup; ( ), number of patients
with the same deletion.
aIn-frame mutation by prediction.
bMutations that have not been reported in the literature.
Table 6. Exon Duplication for Patients With Duchenne Muscular
Dystrophy and Becker Muscular Dystrophy.
50 Hot Spot
(Exons 3-19)
30 Hot Spot
(Exons 42-60) Others
Duchenne
muscular
dystrophy
Dup 2 Dup 44-45a,b Dup 22-23b
Dup 3-44a Dup 45
Dup 17-19 Dup 56-70b
(n ¼ 3) (n ¼ 3)
Becker muscular
dystrophy
Dup 3-12a
(n ¼ 1)
Abbreviation: n, number of patient for each subgroup.
aIn-frame mutation by prediction.
bMutations that have not been reported in the literature.
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StatisticsDepartmentWebsite:www.censtatd.gov.hk).Whencom-
pared with the population-based prevalence of dystrophinopathy of
1.3 to 1.8 per 10 000males aged 5 to 24 years in 2007 of 4 States of
UnitedStates,8 our prevalence rate is slightly lower but comparable.
Genetic Mutation
The overall percentage of exon deletions (49.3%, 95% confidence
interval 37.6%-61.1%) ofourwhole groupof patients is lower than
the figures of60% to 70% generally found in theprevious overseas
studies,9-13 though this is statistically significant only in the Duch-
enne muscular dystrophy group in which only 45.3% (95% confi-
dence interval 33.7%-57.4%) of patients have exon deletions. On
the contrary, there is a significantly higher percentage of point
mutations or small rearrangements up to 40.6% (95% confidence
interval 29.5%-52.9%) in our Duchenne muscular dystrophy
group, in contrast to the lower percentage of 10.4% reported in the
US population-based study,9 15% in the Czech Republic and Slo-
vakia registry,10 20% in the comprehensive Leiden DMD muta-
tion database,11 24.5% in the Japanese national registry,12 and
26% in the French UMD- Duchenne muscular dystrophy multi-
center database.13 The 9.3% exon duplication in our overall Duch-
enne muscular dystrophy and Becker muscular dystrophy groups
is similar to the reported 6% to 13% in other studies.9-13 As these
percentage figures have influence on one another, we cannot draw
conclusion yet whether the lower percentage of exon deletions is
secondary to a genuinely higher percentage of point mutations
or small rearrangements, and vice versa. A similar findings were
also noted in an earlier study.14 Out-of-phase mutations were
noted in both the Duchenne and Becker groups. For those identi-
fiedmutationswith exon deletion/duplication, 13.9% of theDuch-
enne group had in-frame deletion by prediction, and 27.3% of the
Becker group had out-of-frame mutation by prediction.
Steroid Therapy
In this study, only 25.3% of the patients in the Duchenne group
were treated with steroid. This is lower when compared to 41%
in Japan12 and 61% in the international DuchenneConnect
Registry from America.15 The mean steroid starting age in our
group was 8 years. Comparing our findings of steroid starting age
with those reported in theBritish study at 6.4 years,16 and the stan-
dard of care recommendation between 4 and 6 years,17 our
patients had a later steroid starting age. With the introduction of
steroid at late ambulatory stage, the motor beneficial effect on
ambulation is limited. It is understandablewhymost childrenonly
continued steroid for a short period of time as most of them
stopped steroidwhen they lost ambulation.This important finding
had been shared among local health professionals in 2012 to
increase the awareness of the steroid treatment for Duchenne
muscular dystrophy. For the past 2 years, more children with
Duchenne muscular dystrophy have been started on steroid and
at an earlier age between 4 and 6 years. Ongoing education to par-
ents, pediatricians, and other medical specialists on the evidence-
based long-termbenefits of steroid and to continue such treatment
even during the nonambulatory stage is necessary. Use of steroid
among Becker muscular dystrophy remains controversial.
Interventions Required
When compared the treatment of our patients having Duchenne
muscular dystrophy with those of the Japanese registry,12 we
found a similar percentage of patients required cardiac medical
treatment (31% in Hong Kong vs 29.5% in Japan) and noninva-
sive ventilator support (25% in Hong Kong vs 22% in Japan).
In Japan, most ventilated patients (80%) were on noninvasive
ventilation with 20% using invasive ventilation, while in Hong
Kong, all patients were on noninvasive ventilation. For the sco-
liosis surgery, Hong Kong has a much higher percentage of
patients undergone this treatment (23% in Hong Kong vs
3.9% in Japan). This can be explained by the presence of a cen-
tralized orthopedic spine service for whole Hong Kong provid-
ing timely posterior spinal surgery for this group of patients
before critical respiratory deterioration has occurred. Another
possible explanation could be due to the fact that a higher per-
centage of the Japanese patients were using steroid, so the sco-
liosis progression could be milder and hence a smaller number
of patients required such surgery.
Figure 6. Schematic diagram illustrating the distribution of the small mutations. Vertical rectangles represent different exons of the Duchenne
muscular dystrophy gene. Arrows in red ¼ Duchenne muscular dystrophy; arrows in green ¼ Becker muscular dystrophy.
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Swallowing and feeding problems leading to underweight are
common in Duchenne muscular dystrophy in early adulthood.
This could be due to degeneration of smooth muscle in the gastro-
intestinal tract due to dystrophin deficiency leading togastrointest-
inal symptoms. Gastrostomy has been recommended in the
Standard of Care guideline.17,18 Of the 21 patients with Duchenne
muscular dystrophymore than20years old inour study, only2had
undergone gastrostomy in their 20s by 2012. In Japan, Mizuno
et al19 reported their experienceof77patientswithDuchennemus-
cular dystrophy who had undergone gastrostomy between 2007
and 2009. The median age for gastrostomy was 26 years (range
13-47 years). The introduction of gastrostomy feeding resulted
in ameliorationofmalnutrition, swallowingdifficulty, and respira-
tory status; most complications were tolerable with respiratory
failure and peritonitis as the2main concerns.19 In France, between
1997 and 2007, 25 patients with Duchenne muscular dystrophy
had gastrostomy at themedian ageof 23 years (range 11-28years).
Improved weight-for-age ratio from 69% to 87%was noted when
the patients were followed up at 2 years. Complications occurred
in 84% of patients but were all well tolerated.20 Earlier sharing of
our findings with local pediatricians had raised awareness on the
needofgastrostomyfeedingandacoordinatedcentralized surgical
service to allow such group of patients to benefit from this
intervention timely with low risk of complications. Since then
more patients with DMD and other severe neuromuscular
disorders had undergone gastrostomy in our locality.
Need of Patient Registry
Currently a number of phase 2 and phase 3 clinical trials on poten-
tial treatments forDuchennemuscular dystrophy/Beckermuscular
dystrophy are activelyongoingaround theworld.Among themany
different clinical drug trials, some are targeted on genetic therapy.
These include the antisense oligonucleotides using exon 51-
targeting phosphorodiamidate morpholino oligomers21 for those
whohad specific exondeletions that canbenefit fromexon51 skip-
ping, and the research drug to induce ribosomal read through of the
premature termination mutation due to small rearrangement or
point mutation.22,23 As different potential therapeutic drugs target
at different patient cohorts of specific mutations and clinical
profiles, setting up of national registry will facilitate more rapid
identification and selectionof suitable candidates for suchpurpose.
Although Duchenne muscular dystrophy/Becker muscular
dystrophy national registries have been set up in over 30 countries,
a global registry for Duchenne Muscular Dystrophy has also been
established.24 This first territory wide study in Hong Kong on this
group of patients provides clear evidence that such registry could
be set up involving all participating centers in Hong Kong.
Maintenanceof such registry required the support from local health
authority, the clinical teams, and the patient support group.
Study Limitation
There are a few limitations in the current study. Although
Hospital Authority (HA) in Hong Kong is taking care of over
90% of our local population, the coverage is not 100%. Some
of the patients especially those with milder Becker muscular
dystrophy presentation could remain undiagnosed until they
reached adulthood or only had their follow-up in the private
hospitals instead of HA hospitals. Also in a few HA hospitals,
when patients with Duchenne muscular dystrophy had their
age reached 18 years or over, they were transferred to the
adult services to continue the medical care, so this group of
patients could have been missed out in this study as we were
collecting data only from the pediatric neurology depart-
ments, but this number is expected to be small. Therefore, the
local prevalence calculated from this study is a reasonable
good estimate of the situation in Hong Kong with a possibility
of only slight underestimation. With a study design of retro-
spective review, some of the collected information including
the age at diagnosis and the definition of cardiomyopathy
among different centers were incomplete, so further analysis
on these aspects is not possible.
Conclusion
This first territory wide study for individuals with dystrophino-
pathy in Hong Kong suggests a slightly lower but comparable
prevalence with the Western countries. Compared with other
studies, we have a higher percentage of point mutations and a
lower percentage of exon deletions in the Duchenne muscular
dystrophy group. The findings in this study are unique and reli-
able aswewere able to capture almost all the patientswithDuch-
enne muscular dystrophy under the age of 18 years in Hong
Kong to be included in this study, and the genetic study is per-
formed in a centralized accredited genetic diagnostic service.
The study also provides valuable information on some aspects
of the natural history of our patients and themultispecialty inter-
ventions they were receiving, which could potentially allow us
to develop more robust clinical management strategies for this
group of patients. This study serves as a prelude to the develop-
ment of registry with the objective of establishment of an
ongoing Duchenne muscular dystrophy–Becker muscular dys-
trophy registry and allows possible future coordination for clin-
ical trial readiness and better multidisciplinary care.
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